PDCD1 and Autoimmunity: These targeted bispecifics, hereafter referred to as PD-1 agonist ImmTAAI (immune modulating monoclonal TCR against autoimmunity) molecules, effectively act as a bridge, ensuring PD-1 agonism occurs in cis with TCR engagement on the attacking autoreactive T cell.